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The immunologic role of thymectomy in the treatment of
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Background and Purpose: Thymectomy is generally accepted as the major option of
treatment for myasthenia gravis. To elucidate the biological role of thymectomy in
the treatment of myasthenia gravis, the immunologic characteristics of the thymus
was studied in association with the postoperative kinetics of the anti-acetylcholine
receptor antibody titer.
Materials and Methods: Thirty-four patients with nonthymomatous myasthenia
gravis who had positive anti-acetylcholine receptor antibody titer and undergoing
extended thymectomy were subjected to the study. Reduction of anti-acetylcholine
receptor antibody titer was evaluated in terms of the proportion of anti-acetylcholine
receptor antibody titer at 1 year after thymectomy to that before the operation. The
numbers of B lymphocytes (CD19 cells) and the germinal center B lymphocytes
(CD19CD38high cells) present in 1 g of the thymic tissue were calculated by flow
cytometry.
Results: The proportion of anti-acetylcholine receptor antibody titer at 1 year after
thymectomy ranged from 27.5% to 150%. The numbers of B lymphocytes and the
germinal center B lymphocytes in 1 g of the thymic tissue ranged from 0.19 106/g
to 162.8  106/g and from 0.09  106/g to 33.4  106/g, respectively. The
proportion of anti-acetylcholine receptor antibody titer at 1 year after thymectomy
had a significant inverted correlation with the number of B lymphocytes (P  .002)
as well as that of the germinal center B lymphocytes (P  .007).
Conclusion: Effectiveness of thymectomy was dependent on predominance of B
lymphocytes and the germinal center B lymphocytes in the thymus, suggesting that
one of the biological roles of thymectomy in the treatment of myasthenia gravis is
removing the thymus-associated germinal centers.
Myasthenia gravis (MG) is an autoimmune disease character-ized by fatigable muscle weakness. Nicotinic acetylcholinereceptor (AchR) is the major autoantigen in MG, and produc-tion of anti-nicotinic acetylcholine receptor antibody (anti-AchR Ab) is supposed to cause reduction of the number ofAchR at the neuromuscular junction, resulting in muscle
weakness.1-3
MG is widely known for its frequent association with disorders of the thymus
including hyperplasia and thymoma.4-6 Thymectomy has been shown to result in
remission or reduction of MG symptoms in nearly 90% of patients and is generally
accepted as a major option for treatment,7-9 although the operative procedure is still
controversial.10-12 Consistent with improvement of the clinical symptoms, the
anti-AchR Ab titer was shown to decline after thymectomy.13,14
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The typical microscopic appearance in patients with non-
thymomatous MG is follicular hyperplasia characterized by
the prominent germinal centers in the medulla.4,5 Although
the thymus is the central organ for T-lymphocyte differen-
tiation, the germinal center is where B lymphocytes differ-
entiate to the cells producing antibodies with high affinity to
the antigens. Several lines of in vitro studies revealed the
anti-AchR Ab production by the lymphocytes recovered
from the MG thymus,13,15 suggesting the critical role of the
thymic germinal centers in the pathogenesis of MG. How-
ever, the clinical implication of thymus-associated germinal
centers in the MG thymus remain to be clarified.
In the present study, to reveal the clinical significance of
the thymus-associated B lymphocytes in the treatment of
MG, we performed quantitative evaluation of the lympho-
cyte subset in the thymus, in conjunction with transition of
the anti-AchR Ab titer after thymectomy.
Methods
Patients
There were 97 patients with MG who underwent surgical treatment
at Osaka University Hospital between l991 and 2000. The diag-
nosis was done by neurologists on the basis of the clinical symp-
toms, findings of electromyogram, response to edrophonium (Ten-
silon test), and measurement of the anti-AchR Ab titer in the
serum. Other neurologic disorders were critically excluded.
To focus on the immunologic implication of thymectomy in
patients with nonthymomatous MG in this study, 26 patients with
thymomatous MG were excluded. Among the remaining 71 non-
thymomatous patients, 34 patients who met the following criteria
were subjected to the present study: (1) onset of the disease was
after 10 years of age; (2) the serum anti-AchR Ab titer was positive
(so-called “seropositive”); (3) removal of the thymus and the
adjacent fatty tissue (extended thymectomy) was performed; (4)
oral daily dose of more than 10 mg of prednisone or intravenous
high-dose steroid therapy was not administrated before thymec-
tomy; (5) postoperative steroid therapy was not added or postop-
erative oral daily dose of prednisone was not increased before final
evaluation of the anti-AchR Ab titer at 1 year after thymectomy.
Osserman’s classification was type I in 3 patients, type IIA in
11 patients, and type IIB in 20 patients. The patients were in-
formed of the nature of the study and had given consent to the use
of the materials prior to the operation.
Evaluation of Reduction in Serum Anti-AchR
Antibody Titer
Anti-AchR Ab titer was measured by the method of radioimmu-
noassay at Shionogi Laboratory (Osaka, Japan) as previously de-
scribed.15 The reduction of anti-AchR Ab titer was evaluated at 1
year after thymectomy. The proportion of the titer (% Ab) at 1 year
after thymectomy to the preoperative value was calculated.
Histologic Evaluation of the Thymus
Several portions of the resected thymus were subjected to the
routine pathologic examination. Hematoxylin and eosin–stained
sections were prepared from paraffin-embedded blocks and micro-
scopically examined under low magnification (40). The average
number of the germinal centers identified in 1 visual field was
evaluated by counting in 3 to 4 randomly selected visual fields of
at least 2 sections of the resected thymus.
Recovery of Lymphocytes from the Thymus and Flow
Cytometric Analysis
The remaining thymic tissue was weighed, minced with scissors,
pressed against a stainless steel mesh, and the lymphocytes freshly
isolated, as reported previously.16,17 The recovered lymphocytes
were suspended in cold phosphate-buffered saline solution (PBS)
as a single-cell suspension and counted. The total number of the
recovered lymphocytes was divided by the weight of the specimen,
and the number of lymphocytes derived from 1 g of the thymic
tissue was obtained. When a considerable number of erythrocytes
were present in the cell suspension, erythrocytes were removed by
a Ficoll-Hypaque (Lymphoprep, Nycomed, Oslo, Norway) density
gradient. Finally, 1 107 lymphocytes were suspended in 1 mL of
cold PBS before subjected to the flow cytometric study.
Flow Cytometric Analysis of Surface Marker
Expression of the Lymphocytes and Quantitative
Evaluation of B-Lymphocyte Subset
Fluorescein isothiocyanate (FITC)-conjugated anti-human CD19
(a marker of B lymphocytes) and phycoerythrin (PE)-conjugated
anti-human CD38 (a marker of B lymphocytes in the germinal
center) were purchased from DAKO (Glostrup, Denmark) and
Becton-Dickinson (San Jose, Calif), respectively. FITC-conju-
gated control mouse immunoglobulin G (IgG) and PE-conjugated
control mouse IgG were also purchased from Becton-Dickinson.
Surface marker expression was evaluated by flow cytometric
study following the method reported previously.16-18 In brief, 1 
106 lymphocytes were labeled by FITC-conjugated anti-CD19
antibody on ice for 20 minutes, followed by 2 washes in cold PBS.
At least 10,000 events were acquired to evaluate the surface
marker expression with the use of a FACScan cytometer (Becton-
Dickinson), and the data were analyzed by the program Lysis or
Cell Quest (Becton-Dickinson). The negative level of expression
was determined according to the control mouse IgG staining. The
number of B lymphocytes was calculated by the number of lym-
phocytes in 1 g of the thymic tissue and the proportion of CD19
cells.
When the germinal center B lymphocytes were being evalu-
ated, PE-conjugated anti-human CD38 was also added to the cell
suspension, and the simultaneous analysis of CD19 and CD38
expressions by 2-color flow cytometric method was done. The
germinal center B lymphocytes were defined as CD19 cells
expressing CD38 at a high level. The number of germinal center B
lymphocytes was also calculated by the number of lymphocytes in
1 g of the thymic tissue and the proportion of CD19CD38high
cells.
Simultaneous analysis of CD19 and CD38 expressions was
done in 17 patients. In the remaining 17 patients, CD19 expression
alone was evaluated.
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Statistical Analysis
Correlation between 2 variables was calculated by the Pearson
correlation coefficient. Statistical analyses were done with the
SPSS software (SPSS, Inc, Chicago, Ill).
Results
Relationship between the Clinical Outcome and the
Reduction of Anti-AchR Ab Titer
Remission of the myasthenic symptoms was obtained in 4
patients (11.8%), and palliation was obtained in 24 patients
(70.6%) at 1 year after thymectomy. The myasthenic symp-
toms were unchanged and thymectomy was not considered
as effective in the remaining 6 patients (17.6%).
The typical transition of anti-AchR Ab titer after thymec-
tomy is shown in Figure 1. In this patient, anti-AchR Ab
titer decreased slowly during 5 years, and %Ab at 1 year
was 47.1%. Among all patients, %Ab at 1 year ranged from
27.5% to 150%.
Figure 2 shows % Ab at 1 year in each patient of the
groups with remission, palliation, or no change. The mean
% Ab at 1 year was 45.9%, 59.7%, and 93.6% in each
group, respectively; % Ab at 1 year was reduced to less than
60% in 3 of 4 patients (75%) with remission, in 13 of 24
patients (54.2%) with palliation, and in 1 of 6 patients
(16.7%) whose symptoms were unchanged. Thus, reduction
of anti-AchR Ab titer reflected the clinical improvement of
MG.
Relationship between the Clinical Outcome and the
B-Lymphocyte Subset in the Thymus
The number of the lymphocytes recovered from 1 g of the
thymic tissue ranged from 2.9  106/g to 742  106/g.
The representative result of 2-color flow cytometric anal-
ysis on CD19 and CD38 expressions is shown in Figure 3.
Lymphocytes were gated according to the forward and the
side scatter pattern (Figure 3, A). The proportion of CD19
cells was 55% (Figure 3, C). CD38high cells comprised
20.5% of CD19 cells (Figure 3, D), and thus the propor-
tion of CD19CD38high cells was 11.3%. The number of
lymphocytes recovered from the thymic tissue was 294.4 
106/g in this patient, and therefore the numbers of CD19
cells (B lymphocytes) and CD19CD38high cells (the ger-
minal center B lymphocytes) present in 1 g of the thymic
tissue was calculated to be 162.8 106/g and 33.4 106/g,
respectively.
The proportion of CD19 cells ranged from 1.4% to
56.4%. The number of CD19 cells in 1 g of the thymic
tissue ranged widely from 0.19  106/g to 162.8  106/g.
As shown in Figure 4, % Ab at 1 year had a significant
inverted correlation with the number of CD19 cells (B
lymphocytes) in 1 g of the thymic tissue.
The proportion of CD38high cells in the CD19 popula-
tion ranged from 1.2% to 20.5%. The number of
CD19CD38high cells in 1 g of the thymus tissue ranged
widely from 0.09  106/g to 33.4  106/g. As shown in
Figure 5, % Ab at 1 year had a significant inverted corre-
lation with the number of CD19CD38high cells (germinal
center B lymphocytes) in 1 g of the thymic tissue.
Correlation between Flow Cytometric Analysis of B-
Lymphocyte Subset and the Microscopic Appearance
of the Thymus
In 17 cases where expression of both CD19 and CD38
was simultaneously evaluated, microscopic appearance
of the thymus was then examined. Patients were divided
into 3 groups according to the number of the germinal
centers identified microscopically: below 1 (group A), 1
to 2 (group B), and more than 2 (group C). As shown in
Figure 6, the number of germinal center B lymphocytes
identified as CD19CD38high cells by flow cytometry
reflected the abundance of the germinal center in the
microscopic appearance.
Figure 1. The typical transition of anti-AchR Ab titer after
thymectomy.
Figure 2. The clinical outcome and the reduction of anti-AchR Ab
titer.
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Discussion
Although thymectomy is generally accepted as 1 major
option of treatment for MG, the effectiveness of thymec-
tomy differs from a patient to patient, and there is a minor
but considerable population of patients who are not bene-
fited by thymectomy. The microscopic appearance of the
thymus also varies greatly from patient to patient. Instead of
follicular hyperplasia, normal appearance as well as the
involuted thymus are sometimes encountered. The present
study quantitatively evaluated the relationship between im-
munologic characteristics of the MG thymus and the effec-
tiveness of thymectomy and revealed the significance of the
thymus-associated B lymphocytes, especially the germinal
center B lymphocytes, in the reduction of anti-AchR Ab
titer after thymectomy.
Although there have been numerous studies reporting the
effectiveness of thymectomy in the treatment of MG, the
change in clinical symptoms has been adopted as the pa-
rameter to evaluate the effectiveness of thymectomy. It is
not easy to quantitatively evaluate the clinical symptoms,
however. In addition, the severity of clinical symptoms
might be affected by unrelated situations such as infectious
diseases and emotional status. To evaluate the severity of
the disease in a quantitative and objective manner in each
particular patient, we chose the serum anti-AchR Ab titer as
the biological variable. As shown in Figure 2, reduction of
anti-AchR Ab titer reflected improvement of the clinical
symptoms.
Autoantibodies to AchR-associated proteins, but not to
AchR itself, have been suggested to be responsible for
Figure 3. The representative result of flow cytometric analysis. A, Lymphocytes are gated according to the forward
and the side scatter pattern. B, Two-color flow cytometric analysis of CD19 and CD38 expressions. C, B cells are
gated as CD19 cells. D, CD38 expression of CD19 cells. Germinal center B cells are defined as CD19 cells
expressing CD38 at a high level.
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muscle weakness of seronegative MG patients.19 More re-
cently, muscle-specific receptor tyrosine kinase was identi-
fied as the autoantigen in the seronegative MG patients,20,21
indicating that the anti-AchR Ab-negative MG is a disease
distinct from the anti-AchR Ab-positive MG. Anti-AchR
Ab-negative (seronegative) MG patients, therefore, were
excluded from the present study.
Steroid therapy is another major option of treatment for
MG, and it is frequently administered prior to thymectomy.
Because T lymphocytes in the thymus and B lymphocytes in
the germinal center are known to be sensitive to steroid,
administration of high-dose steroid possibly affects the lym-
phocyte population also in the MG thymus. Therefore, the
patients who had daily prednisone dose of more than 10 mg
or those who experienced preoperative steroid pulse therapy
were excluded from the study.
Under the above conditions, based on results obtained
from the seropositive and non-thymomatous patients who
did not have preoperative high-dose steroid therapy, the
present study revealed that reduction of anti-AchR Ab titer
after thymectomy was dependent on abundance of B lym-
phocytes, especially the germinal center B lymphocytes, in
the thymus. The present results suggested that thymectomy
contributes to elimination of anti-AchR Ab–producing cells
in the thymus. Our previous study has shown that the CD4
T-lymphocyte (helper T-cell) subset in the thymus is cor-
related with anti-AchR Ab titer.16 This observation seems
compatible with the result in the present study because
antibody production requires helper T- and B-lymphocyte
interaction and this possibly occurs also in the germinal
centers of the thymus in patients with MG. Our previous
study, however, revealed the abnormal expression of Bcl-2
protein in the thymic germinal centers of the patients with
MG,22 suggesting the possible selection of autoreactive B
lymphocytes in the MG thymus. Further studies remain to
be done to fully reveal the mechanisms of development of
autoreactive B lymphocytes in the MG thymus.
Although reduction of the myasthenic symptoms was
often accompanied by reduction of serum anti-AchR Ab
titer, clinical improvement is observed in some cases where
serum anti-AchR Ab titer remains unchanged after thymec-
tomy. Contrarily, myasthenic symptoms are not relieved in
some cases despite reduction of anti-AchR Ab titer. Several
autoantibodies to the skeletal muscle, such as anti-ryanod-
Figure 4. The correlation between % Ab at 1 year and the number
of CD19 cells (B lymphocytes) present in 1 g of the thymic tissue.
Figure 5. The correlation between % Ab at 1 year and the number
of CD19CD38high cells (the germinal center B lymphocytes)
present in 1 g of the thymic tissue.
Figure 6. Correlation between the number of CD19CD38high cells
and the number of germinal centers identified microscopically.
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ine receptor antibody23 and anti-titin antibody,24 were also
identified and shown to be correlated with clinical severity
of MG.25 The serum titers of these antibodies might have
some role in the clinical outcome of the patients who had
discrepancy in the kinetics of serum anti-AchR Ab titer and
clinical outcome. Further study focusing on the role of the
thymus in production of these autoantibodies remains to be
done.
Because the present study strictly focused on the patients
with nonthymomatous MG, the role of thymectomy in thy-
momatous MG could not be approached. Our recent study
showed that type B1 and B2 thymomas, according to the
World Health Organization histologic classification system,
are significantly more often associated with MG than other
types of thymomas.26,27 Type B thymomas were shown to
induce CD4CD8 cells, the T lymphocytes with the phe-
notype of the cortical thymocytes. The environment pre-
sented by the thymoma neoplastic epithelial cells whose
human leukocyte antigen-DR expression is down-regulated
is supposed to alter the selection mechanisms of
CD4CD8 cells and might be responsible for develop-
ment of autoreactive T lymphocytes and possibly supply
these cells to the peripheral organs.28-34 T-lymphocyte sub-
set, therefore, should be more focused than B-lymphocyte
subset in the patients with thymomatous MG.
In conclusion, at least one of the biological roles of
thymectomy in the treatment of MG was suggested to be the
removal of the thymus-associated germinal centers. To es-
tablish the method for preoperative evaluation of the immu-
nologic characteristics of the thymus seems helpful for
clinical practices, for example, in selecting the patients with
MG who are most benefited by thymectomy.
We are grateful to Ms Reiko Tsubouchi and Ms Chika Ariga
for assistance with the study and to Ms Naoko Araki for secretarial
work.
References
1. Vincent A. Immunology of acetylcholine receptors in relation to
myasthenia gravis. Physiol Rev. 1980;60:756-824.
2. Lindstrom J, Shelton D, Fujii Y. Myasthenia gravis. Adv Immunol.
1988;42:233-84.
3. Vincent A, Willcox N, Hill M, Curnow J, MacLennan C, Beeson D.
Determinant spreading and immune responses to acetylcholine recep-
tors in myasthenia gravis. Immunol Rev. 1998;164:157-68.
4. Willcox N. Myasthenia gravis. Curr Opin Immunol. 1993;5:910-7.
5. Levinson AI, Wheatley LM. The thymus and the pathogenesis of
myasthenia gravis. Clin Immunol Immunopathol. 1996;78:1-5.
6. Marx A, Schultz A, Wilisch A, Helmreich M, Nenninger R, H-K
Mu¨ller-hermelink. Paraneoplastic autoimmunity in thymus tumors.
Dev Immunol. 1998;6:129-40.
7. Masaoka A, Yamakawa Y, Niwa H, et al. Extended thymectomy for
myasthenia gravis patients: a 20-year review. Ann Thorac Surg. 1996;
62:853-9.
8. Ashour MH, Jain SK, Kattan KM, et al. Maximal thymectomy for
myasthenia gravis. Eur J Cardiothorac Surg. 1995;9:461-4.
9. Calhoun RF, Ritter JH, Guthrie TJ, et al. Results of transcervical
thymectomy for myasthenia gravis in 100 consecutive patients. Ann
Surg. 1999;230:555-61.
10. Cooper JD, Al-Jilaihawa AN, Pearson FG, Humphrey JG, Humphrey
HE. An improved technique to facilitate transcervical thymectomy for
myasthenia gravis. Ann Thorac Surg. 1988;45:242-7.
11. Jaretzki A, Wolff M. Maximal thymectomy for myasthenia gravis.
Surgical anatomy and operative technique. J Thorac Cardiovasc Surg.
1988;96:711-6.
12. Masaoka A. Extended trans-sternal thymectomy for myasthenia gravis.
Chest Surg Clin N Am. 2001;11:369-87.
13. Scadding GK, Vincent A, Newsom-Davis J, Henry K. Acetylcholine
receptor antibody synthesis by thymic lymphocytes. Correlation with
thymic histology. Neurology. 1981;31:935-43.
14. Kagotani K, Monden Y, Nakahara K, et al. Anti-acetylcholine receptor
antibody titer with extended thymectomy in myasthenia gravis. J Tho-
rac Cardiovasc Surg. 1985;90:7-12.
15. Fujii Y, Monden Y, Nakahara K, Hashimoto J, Kawashima Y. Anti-
body to acetylcholine receptor in myasthenia gravis: production by
lymphocytes from thymus or thymoma. Neurology. 1984;34:1182-6.
16. Fujii Y, Hayakawa M, Nakahara K. Thymus cells in myasthenia
gravis: a two-colour flow cytometric analysis of lymphocytes in the
thymus and thymoma. J Neurol. 1992;239:82-8.
17. Okumura M, Fujii Y, Inada K, Nakahara K, Matsuda H. Both
CD45RA and CD45RA subpopulations of CD8 T cells contain
cells with high levels of lymphocyte function-associated antigen-1
expression, a phenotype of primed T cells. J Immunol. 1993;150:429-
37.
18. Okumura M, Fujii Y, Takeuchi Y, Inada K, Nakahara K, Matsuda H.
Age-related accumulation of LFA-1(high) cells in a
CD8CD45RA(high) T cell population. Eur J Immunol. 1993;23:
1057-63.
19. Blaes F, Beeson D, Plested P, Lang B, Vincent A. IgG from “sero-
negative” myasthenia gravis patients binds to a muscle cell line,
TE671, but not to human acetylcholine receptor. Ann Neurol. 2000;
47:504-10.
20. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet.
2001;357:2122-8.
21. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific
kinase pathway: new targets for autoimmune and genetic disorders at
the neuromuscular junction. Muscle Nerve. 2002;25:4-16.
22. Shiono H, Fujii Y, Okumura M, Takeuchi Y, Inoue M, Matsuda H.
Failure to down-regulate Bcl-2 protein in thymic germinal center B
cells in myasthenia gravis. Eur J Immunol. 1997;27:805-9.
23. Mygland A, Tysnes O-B, Matre R, Volpe P, Aarli JA, Guilhus NE.
Ryanodine receptor autoantibodies in myasthenia gravis patients with
a thymoma. Ann Neurol. 1992;32:589-91.
24. Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in
patients with late onset myasthenia gravis: clinical correlations. Auto-
immunity. 1995;20:99-104.
25. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia
gravis correlates with the serum concentration of titin and Ryanodine
receptor autoantibodies. Arch Neurol. 2000;57:1596-600.
26. Okumura M, Ohta M, Tateyama H, et al. WHO histologic classifica-
tion reflects oncological behaviors of human thymoma. A clinical
study of 273 patients. Cancer. 2002;94:624-32.
27. Okumura M, Miyoshi S, Fujii Y, et al. Clinical and functional signif-
icance of WHO classification on human thymic epithelial neoplasms.
A study of 146 consecutive tumors. Am J Surg Pathol. 2001;25:103-
10.
28. Willcox N, Schluep M, Ritter MA, Schuurman HJ, Newsom-Davis J,
Christenson B. Myasthenic and nonmyasthenic thymoma. An expan-
sion of a minor cortical epithelial cell subset? Am J Pathol. 1987;127:
447-60.
29. Fujii Y, Hayakawa M, Inada K, Nakahara K. Lymphocytes in thy-
moma: association with myasthenia gravis is correlated with increased
number of single-positive cells. Eur J Immunol. 1990;20:2355-8.
30. Mu¨ller-Hermelink HK, Wilisch A, Schultz A, Marx A. Characteriza-
tion of the human thymic microenvironment: lymphoepithelial inter-
action in normal thymus and thymoma. Arch Histol Cytol. 1997;60:
9-28.
31. Inoue M, Okumura M, Miyoshi S, et al. Impaired expression of MHC
Okumura et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 6 1927
G
TS
class II molecules in response to interferon-gamma (IFN-gamma) on
human thymoma neoplastic epithelial cells. Clin Exp Immunol. 1999;
117:1-7.
32. Hoffacker V, Schultz A, Tiesinga JJ, et al. Thymomas alter the T-cell
subset composition in the blood: a potential mechanism for thymoma-
associated autoimmune disease. Blood. 2000;96:3872-9.
33. Nagvekar N, Moody AM, Moss P, et al. A pathogenetic role for the
thymoma in myasthenia gravis. Autosensitization of IL-4- producing T
cell clones recognizing extracellular acetylcholine receptor epitopes
presented by minority class II isotypes. J Clin Invest. 1998;101:2268-
77.
34. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Ma-
ture, long-lived CD4 and CD8 T cells are generated by the thy-
moma in myasthenia gravis. Ann Neurol. 2001;50:64-72.
Discussion
Dr Steven J. Mentzer (Boston, Mass). If I understood this
correctly, you think that the supply of the antibody-producing cells
originates in the thymus. You believe the delay in resolution of
MG is not due to the fact that you have eliminated the entire
population of antibody-producing cells, but that you have elimi-
nated the organ producing these cells.
Dr Okumura. The first onset might occur in the peripheral
organs, but after the sensitization of the T lymphocytes, those T
lymphocytes can move to the thymus and there form germinal
centers. The B lymphocytes come peripherally to the germinal
centers in the thymus and there develop into the antibody-produc-
ing cells with higher affinity antibody. Those cells go out to the
periphery again. Therefore, the central site of high-affinity anti-
body-producing cells in the patients with MG is probably the
thymus.
Dr Ross M. Bremner (Los Angeles, Calif). Your conclusion
was that some of these thymus glands do not have a lot of B cells
and the outcome of thymectomy in those patients is not as good as
the outcome in those that have a lot of B cells. Can you get that
information just from a biopsy or do you need to remove the entire
thymic gland?
Dr Okumura. Previously we did those kinds of experiments.
We actually biopsied bone marrow cells, lymph nodes, by cultur-
ing those cells in vitro, and those B lymphocytes can produce
anti-acetylcholine antibodies.
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